Related references
Note: Only part of the references are listed.BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak
Han Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
Nicholas Di Bella et al.
BLOOD (2010)
Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib
Siquan Chen et al.
CANCER RESEARCH (2010)
Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells (Publication with Expression of Concern. See vol. 26, pg. 1531, 2020)
Rekha Rao et al.
CLINICAL CANCER RESEARCH (2010)
Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2010)
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Luca Paoluzzi et al.
CLINICAL CANCER RESEARCH (2010)
Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
John J. Wright
CLINICAL CANCER RESEARCH (2010)
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells
Maria Baou et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation A MECHANISTIC BASIS FOR ENZASTAURIN-DEATH LIGAND SYNERGY
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Perturbation of the Bcl-2 Network and an Induced Noxa/Bcl-xL Interaction Trigger Mitochondrial Dysfunction after DNA Damage
Hernando Lopez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The Anti-apoptotic Protein BCL2L1/Bcl-xL Is Neutralized by Pro-apoptotic PMAIP1/Noxa in Neuroblastoma, Thereby Determining Bortezomib Sensitivity Independent of Prosurvival MCL1 Expression
Judith Hagenbuchner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex
Alan D. Brooks et al.
MOLECULAR CANCER RESEARCH (2010)
The BCL-2 Family Reunion
Jerry E. Chipuk et al.
MOLECULAR CELL (2010)
BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
Decheng Ren et al.
SCIENCE (2010)
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Judith E. Karp et al.
BLOOD (2009)
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis
E. M. Michalak et al.
CELL DEATH AND DIFFERENTIATION (2009)
A phase II study of bortezomib in patients with MALT lymphoma
Marlene Troch et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis
Haiming Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
MECHANISMS OF DISEASE Cell Death
Richard S. Hotchkiss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IFN-α and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis
Gregory B. Lesinski et al.
CANCER RESEARCH (2008)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-XL Inhibitor, ABT-737
Kenji Okumura et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region
Karthikeyan Kandasamy et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Bortezomib: Putting mantle cell lymphoma on death row
Andrew H. Wei et al.
LEUKEMIA & LYMPHOMA (2008)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?
Jerry E. Chipuk et al.
TRENDS IN CELL BIOLOGY (2008)
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
NATURE REVIEWS CANCER (2008)
MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Bcl-2-regulated apoptosis: mechanism and therapeutic potential
Jerry M. Adams et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib
Jens Voortman et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells
Xiangguo Liu et al.
CANCER RESEARCH (2007)
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death
Concetta Conticello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D. Chauhan et al.
ONCOGENE (2007)
Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity
Son B. Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Ultraviolet radiation triggers apoptosis of fibroblasts and skin keratinocytes mainly via the BH3-only protein Noxa
Edwina Naik et al.
JOURNAL OF CELL BIOLOGY (2007)
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206
Kristie A. Blum et al.
LEUKEMIA & LYMPHOMA (2007)
Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa
Andrew M. Fribley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Loss of caspase-9 provides genetic evidence for the type I/II concept of CD95-mediated apoptosis
Ajoy K. Samraj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
BH3-only proapoptotic Bcl-2 family members Noxa and Puma mediate neural precursor cell death
Rizwan S. Akhtar et al.
JOURNAL OF NEUROSCIENCE (2006)
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
Albert F. Kabore et al.
APOPTOSIS (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Michael Certo et al.
CANCER CELL (2006)
How the Bcl-2 family of proteins interact to regulate apoptosis
MF van Delft et al.
CELL RESEARCH (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Life in the balance: how BH3-only proteins induce apoptosis
SN Willis et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells
JZ Qin et al.
CANCER RESEARCH (2005)
Differential regulation of noxa in normal Melanocytes and melanoma cells by proteasome inhibition:: Therapeutic implications
Y Fernández et al.
CANCER RESEARCH (2005)
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
RA Mesa et al.
BLOOD (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins
SN Willis et al.
GENES & DEVELOPMENT (2005)
BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly
T Kuwana et al.
MOLECULAR CELL (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Cytochrome C-mediated apoptosis
XJ Jiang et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2004)
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
XW Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai et al.
CANCER CELL (2002)
The BCL2 family: Regulators of the cellular life-or-death switch
S Cory et al.
NATURE REVIEWS CANCER (2002)
BH3 domains: intracellular death-ligands critical for initiating apoptosis
T Chittenden
CANCER CELL (2002)
Keeping killers on a tight leash: transcriptional and posttranslational control of the pro-apoptotic activity of BH3-only proteins
H Puthalakath et al.
CELL DEATH AND DIFFERENTIATION (2002)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function
WA Cliby et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
EHYA Cheng et al.
MOLECULAR CELL (2001)
Solution structure of the antiapoptotic protein bcl-2
AM Petros et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
E Oda et al.
SCIENCE (2000)
Induction of apoptosis by cancer chemotherapy
SH Kaufmann et al.
EXPERIMENTAL CELL RESEARCH (2000)
Share Paper
